GSK Reports Improved Outlook Despite US Drug Tariffs

GSK reports improved outlook despite US drug tariffs

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter.

News: GSK Reports Improved Outlook Despite US Drug Tariffs

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter. Group sales increased one percent to £8 billion, helped by a 36 percent increase in cancer treatments that offset falls for other drugs, including for influenza. powered by Auto Youtube Summarize Related posts: News: India exporters steel themselv…

GSK Raises 2025 Guidance After Strong Q2 Performance

GSK Plc (LON:GSK) has announced 2nd quarter results. Strong Specialty Medicines performance drives sales and core operating profit growth•Total Q2 2025 sales £8.0 billion +1% AER; +6% CER•Specialty Medicines sales £3.3 billion (+15%); Respiratory, Immunology & Inflammation £1.0 billion (+10%); Oncology £0.5 billion (+42%); HIV sales £1.9 billion (+12%)•Vaccines sales £2.1 billion (+9%); Shingrix £0.9 billion (+6%); Meningitis vaccines £0.4 billi…